quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 19, 2026

The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look

View original at finance.yahoo.com
“lifted cash to $18.2B at year-end 2025 from $3.3B a year earlier.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Analyst consensus target price for Pfizer is $29.19

    60% confidence

  • Analyst target price for SoFi Technologies is $21.10

    60% confidence

  • Analyst target price for AT&T is $30.37

    60% confidence

  • Pfizer's non-COVID portfolio achieved 9% operational revenue growth

    60% confidence

  • Equity markets are trading at elevated multiples in May 2026

    60% confidence

  • AT&T legacy wireline revenue declined more than 20% in 2026

    60% confidence

  • AT&T grew its cash position from $3.3 billion at year-end 2024 to $18.2 billion at year-end 2025

    60% confidence

  • SoFi Q1 2026 loan originations reached a record $12.18 billion, up 68% year-over-year

    60% confidence

  • AT&T's converged connectivity and growing free cash flow makes the dividend durable

    60% confidence

  • Pfizer faces a $1.5 billion revenue headwind in 2026 from loss of drug exclusivity and Most Favored Nation drug pricing pressure

    60% confidence

  • AT&T Q1 2026 adjusted EPS grew 11.8% year-over-year to $0.57

    60% confidence

  • SoFi Q1 2026 net income increased 134% year-over-year to $166.7 million

    60% confidence

Data points we hold from this source

AT&T Inc. · debt173.99 USD
AT&T Inc. · analyst target price30.37 USD
AT&T Inc. · forward pe11 multiple
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look — Source | Via News | pt.VIA.NEWS